741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone.
Authors
Hubner, Richard AChen, L
Li, C
Bodoky, G
Dean, A
Lee, K
Cunningham, D
Siveke, J
Braiteh, F
de Jong, F
Belanger, B
Walls, R
Mody, P
von Hoff, D
Wang-Gillam, A
Affiliation
Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2017-09
Metadata
Show full item recordCitation
741P Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx369.124Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.124/4108827/741PPrognostic-value-of-baselineType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx369.124